# Opus Genetics, Inc.: Form 10-Q for the period ended Mar 31, 2019

- Company: [Opus Genetics, Inc.](/companies/ird.md) (CIK 1228627)
- Form: 10-Q
- Filed: 2019-05-10
- Accepted by EDGAR: May 10, 2019, 16:16 ET
- Period: 2019-03-31
- Accession: 0001140361-19-008945
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1228627/000114036119008945/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1228627/000114036119008945/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $3.0m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | −$3.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | −$2.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | −$0.62 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | −$4.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2019-03-31 | $19.0m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $19.4m | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $2.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $3.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $15.9m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1228627/000114036119008945/form10q.htm

Filed May 10, 2019.
Source: SEC EDGAR, the filing index for accession 0001140361-19-008945. Last ingested by Listed: Nov 12, 2026, 19:22 ET. No prices; not investment advice.
